Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics

Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics

Doravirine is a novel nonnucleoside reverse transcriptase inhibitor in development for use with other antiretroviral therapies to treat human immunodeficiency virus type 1 (HIV-1) infection. Doravirine metabolism predominantly occurs via cytochrome P450 3A with

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrobial agents and chemotherapy 2018-08, Vol.62 (8)
Hauptverfasser: Ankrom, Wendy, Yee, Ka Lai, Sanchez, Rosa I, Adedoyin, Adedayo, Fan, Li, Marbury, Thomas, Preston, Richard A, Iwamoto, Marian, Khalilieh, Sauzanne G
Format: Artikel
Sprache:eng
Schlagworte:
Anti-HIV Agents
Antiviral Agents
Kidney
Pyridones
Renal Insufficiency, Chronic
Triazoles
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Doravirine is a novel nonnucleoside reverse transcriptase inhibitor in development for use with other antiretroviral therapies to treat human immunodeficiency virus type 1 (HIV-1) infection. Doravirine metabolism predominantly occurs via cytochrome P450 3A with
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.00326-18